1-(吡啶-2-基)哌啶-4-醇 | 199117-78-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(吡啶-2-基)哌啶-4-醇
• 中文别名: 4-羟基-1-(吡啶-2-基)-哌啶
• 英文名称: 1-(pyridin-2-yl)-4-piperidinol
• 英文别名: N-(2-pyridinyl)-4-hydroxypiperidine；1-(pyridin-2-yl)piperidin-4-ol；N-(2-Pyridyl)-4-piperidinol；1-(2-pyridyl)-4-piperidinol；1-pyridin-2-ylpiperidin-4-ol
• CAS: 199117-78-7
• 化学式: C₁₀H₁₄N₂O
• mdl: MFCD01471641
• 分子量: 178.234
• InChiKey: UCNPUVAHPJTRPG-UHFFFAOYSA-N

物化性质

• 沸点：
  340.7±32.0 °C(Predicted)
• 密度：
  1.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R22
• 海关编码：
  2933990090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-(吡啶-2-基)哌啶-4-醇 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 4-<1-(pyridin-2-yl)piperidin-4-yloxy>benzaldehyde
  参考文献：
  名称：

  Novel Euglycemic and Hypolipidemic Agents. 4. Pyridyl- and Quinolinyl-Containing Thiazolidinediones

  摘要：

  A series of substituted pyridyl- and quinolinyl-containing 2,4-thiazolidinediones having interesting cyclic amine as a linker have been synthesized. Both unsaturated thiazolidinediones 5 and saturated thiazolidinediones 6 and their various salts were evaluated in db/db mice for euglycemic and hypolipidemic effects and compared with BRL compound 11 and BRL-49653, respectively. Some of the potent compounds were converted to various salts in order to obtain improved activities. Among all the salts evaluated, the maleate salt of unsaturated TZD 5a was found to be a very potent euglycemic and hypolipidemic compound. Some of the more interesting compounds have also been evaluated in ob/ob mice and compared with rosiglitazone (maleate salt of BRL-49653). Oral glucose tolerance tests were performed in both db/db and ob/ob mice. Pharmacokinetic studies of 5a maleate are also reported. Receptor binding studies of PPAR gamma by 5a/5a maleate did not show any significant transactivation of PPAR alpha or PPAR gamma.

  DOI：

  10.1021/jm980622j
• 作为产物：
  描述：

  1-(2-吡啶基)-4-哌啶酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以90%的产率得到1-(吡啶-2-基)哌啶-4-醇
  参考文献：
  名称：

  有机三氟硼酸基砌块的合成及微反应

  摘要：

  铜催化的各种有机卤化物与双（频哪醇）二硼的硼化反应可以制备多种有机三氟硼酸钾。这些反应温和且通用，可提供各种有趣的含硼结构单元，包括那些含有哌啶、吡咯、氮杂环丁烷、四氢吡喃和氧杂环丁烷亚结构的结构单元。报告了选定实例的代表性 Minisci 反应。

  DOI：

  10.1021/jo4005519

文献信息

• [EN] INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE<br/>[FR] INHIBITEURS DE LA DIHYDROCÉRAMIDE DÉSATURASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：CENTAURUS THERAPEUTICS

  公开号：WO2019140188A1

  公开（公告）日：2019-07-18

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

  本文披露了二氢神经酰胺脱饱和酶1（Des1）抑制剂化合物和组合物，这些化合物和组合物在治疗疾病方面非常有用，例如代谢紊乱，预期通过抑制Des1对患者具有治疗作用。还提供了在人类或动物受试者中抑制Des1活性的方法。
• [EN] NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO<br/>[FR] NOUVEAUX COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS CORRESPONDANTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010149684A1

  公开（公告）日：2010-12-29

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R1, R2, R3, n, p, q, and Ar are as defined herein, including stereoisomers, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明公开了具有结构(I)的新化合物，其在患者中治疗各种与代谢相关的病症具有实用性：其中R1、R2、R3、n、p、q和Ar如本文所定义，包括立体异构体、溶剂合物和药学上可接受的盐。还公开了包含本发明化合物的药物组合物，以及关于其在有需要的患者中使用的方法。
• Indoline Derivatives I: Synthesis and Factor Xa (FXa) Inhibitory Activities
  作者：Tetsuji Noguchi、Naoki Tanaka、Toyoki Nishimata、Riki Goto、Miho Hayakawa、Atsuhiro Sugidachi、Taketoshi Ogawa、Fumitoshi Asai、Yumi Matsui、Koichi Fujimoto

  DOI：10.1248/cpb.54.163

  日期：——

  A series of bisamidine derivatives each having a ring structure in the center of the molecule was synthesized and their Factor Xa (FXa) inhibitory activities were evaluated. Among them, some indoline derivatives showed potent inhibitory activities in vitro. In particular, (R)-18a having an (R)-configuration at the 2-position of the indoline ring exhibited the most potent FXa inhibitory activity in vitro, more potent than DX-9065a. Furthermore, (R)-18a exhibited more potent anticoagulant activity than DX-9065a. We also succeeded in obtaining an X-ray crystal structure of FXa bound with (R)-18a.

  合成了一系列每个分子中心具有环结构的双氨基衍生物，并评估了它们对Xa因子（FXa）的抑制活性。其中，一些吲哚啉衍生物在体外显示出明显的抑制活性。特别是，具有(R)-构型的(R)-18a在吲哚啉环的2位表现出最强的FXa抑制活性，优于DX-9065a。此外，(R)-18a的抗凝活性也超过了DX-9065a。我们还成功获得了与(R)-18a结合的FXa的X射线晶体结构。
• Azabenzimidazole derivative having AMPK-activating activity
  申请人：Kojima Eiichi

  公开号：US09567330B2

  公开（公告）日：2017-02-14

  Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, or substituted or unsubstituted alkyl, R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl or the like, with the proviso that R1, R2 and R3 are not simultaneously hydrogen, X is a single bond, —S—, —O—, —NR5—, —C(═O)— or the like, R5 is hydrogen, or substituted or unsubstituted alkyl, Y is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl or the like.

  本公开了一种作为AMPK激活剂有用的化合物。一种由以下公式表示的化合物：或其药学上可接受的盐，其中R4是氢，或取代或未取代的烷基，R1、R2和R3各自独立地是氢、卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基或类似物，但R1、R2和R3不能同时是氢，X是单键，-S-，-O-，-NR5-，-C(═O)-或类似物，R5是氢，或取代或未取代的烷基，Y是取代或未取代的环烷基，取代或未取代的环烯基，取代或未取代的杂环烷基或类似物。
• [EN] 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES<br/>[FR] DERIVES DE 1H-[1,2,3]TRIAZOLO[4,5-C]PYRIDINE-4-CARBONITRILE
  申请人：ORGANON NV

  公开号：WO2011086125A1

  公开（公告）日：2011-07-21

  The invention relates to 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derived Cathepsin S inhibitors of Formula (I), wherein R1 is H or (C1-3)alkyl; R2 is halogen or (C1-4)alkyl, optionally substituted with one or more halogens; n is 1 -3; X is O or CH2; U, V and W are CH; or one of U, V and W is N; Y is a group capable of interacting with the Sn....S2 substites of the active site of Cathepsin S; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S related diseases such as atherosclerosis, obesity, inflammation and immune disorders, such as rheumatoid arthritis, psoriasis, cancer, and chronic pain, such as neuropathic pain.

  该发明涉及到1H-[1,2,3]三唑并[4,5-c]吡啶-4-碳腈衍生的Cathepsin S抑制剂的化合物(I)的公式，其中R1为H或(C1-3)烷基；R2为卤素或(C1-4)烷基，可选地取代一个或多个卤素；n为1-3；X为O或CH2；U、V和W为CH；或者U、V和W中的一个为N；Y为能够与Cathepsin S活性位点的Sn....S2取代基相互作用的基团；或其药学上可接受的盐，以及包含它们的药物组合物，以及这些衍生物用于制备用于治疗与Cathepsin S相关疾病的药物，如动脉粥样硬化、肥胖、炎症和免疫紊乱，如类风湿关节炎、牛皮癣、癌症和慢性疼痛，如神经病性疼痛。